Previous Close | 6.38 |
Open | 6.28 |
Bid | 6.25 x 100 |
Ask | 6.31 x 100 |
Day's Range | 6.24 - 6.35 |
52 Week Range | 3.80 - 10.90 |
Volume | |
Avg. Volume | 721,226 |
Market Cap | 823.025M |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.09 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.00 |
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the prod
In the most recent trading session, Cytek Biosciences, Inc. (CTKB) closed at $6.01, indicating a -0.33% shift from the previous trading day.
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™) technology, designed for streamlining workflows, expediting discoveries, and enhancing efficiency, will b